Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
NCT ID: NCT01707628
Last Updated: 2014-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
98 participants
INTERVENTIONAL
2012-10-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early group after rituximab
Patients who received rituximab last dose 3-6 months before influenza vaccination will be the "early group".
influenza vaccination with influenza vaccine
Late group after rituximab
Patients who received rituximab last dose 9-12 months before influenza vaccination will be the "late group".
influenza vaccination with influenza vaccine
Control group
Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls.
influenza vaccination with influenza vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
influenza vaccination with influenza vaccine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Completion of rituximab therapy in the last twelve months before start of the study.
3. Age ≥ 18 years.
4. Signing of informed consent.
Exclusion Criteria
2. Fever at time of vaccination.
3. Previous/known allergic reaction to any of the components of the vaccines given.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Antonius Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
M. Rab
Drs.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minke AE Rab, Drs.
Role: PRINCIPAL_INVESTIGATOR
St. Antonius Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Canisius Wilhelmina Hospital
Nijmegen, Gelderland, Netherlands
Onze Lieve Vrouwen Gasthuis
Amsterdam, North Holland, Netherlands
Medisch Spectrum Twente
Enschede, Overrijssel, Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, Provincie Friesland, Netherlands
Reinier de Graaf Groep
Delft, South Holland, Netherlands
Albert Schweitzer Hospital
Dordrecht, South Holland, Netherlands
St. Antonius Hospital
Nieuwegein, Utrecht, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL37320.100.11
Identifier Type: -
Identifier Source: org_study_id